TORRENT PHARMACEUTICALS

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group. It is based in the Indian city of Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.Torrent Pharma is active in the therapeutic areas of Cardiovascular (CV), central nervous system (CNS), gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. Torrent Pharma’s competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in over 40 countries. Torrent Pharma is committed towards “not just healthcare but life care.”The Core Values, which Torrent believes in and constantly strives to build, are: Integrity, Passion for Excellence, Participative Decision Making, Concern for Society & Environment, Fairness with Care and Transparency. Each of these Timeless Values, a Pillar of Strength, ensures their longevity.COVID-19 RESPONSE:Torrent Group announced its support of Rs. 100 crores to strengthen the Government’s efforts to fight the COVID-19 pandemic and its fallout on poorer sections of our society. This contribution was made to the PM-CARES Fund and for various initiatives such as providing essential medicines to various Govt. hospitals free of cost, contributions to State Government relief funds, contributions to NGOs doing grassroots work to address the issues arising from the COVID-19 pandemic, provision of PPEs to healthcare workers and their own direct efforts to contain the impact of the COVID-19 pandemic on the vulnerable sections of society. In addition to the above, Torrent Group ensured that its employees (including thousands of contract and construction workers working under their contractors) were paid full wages for the entire duration of the lockdown and the entire cost of the same was borne by the Group.Their shareholding pattern consists of Promoters and Promoter Group having 71.25% of shares, Public having 8.68% shares, following by FII’s having 11.65% shares and DII’s with 8.42% shares.